CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 21 No. 11
Pages: 1  2  
Next
Closing Thoughts 

Martin D. Abeloff, MD: Tributes and recollections

October 1, 2007

We at the Cleveland Clinic patterned our cancer center on the model established by Marty Abeloff and his team, incorporating Hematology and Oncology into the administrative structure, and Marty was tremendously helpful in sharing insights into how he achieved that in a complex academic structure. His leadership in breast cancer research, the standards that he has set over the years, and his ability to integrate outstanding science and scientists with a top notch clinical cancer program are just a few of the lasting gifts that he has left with us.

Derek Raghavan, MD, PhD
Cleveland Clinic

Marty Abeloff was one of the strongest and most loved oncology leaders of our time. He shaped our thinking on research, policy, and care in so many ways. I don't think I ever made a decision on an important issue without first running it by Marty. He always had time for me and, I suspect, for everyone who yearned to benefit from his wisdom. His legacy will last for a long, long time.

 

Margaret Tempero, MD
UCSF Cancer Center

Marty Abeloff gave me and my colleagues sage and good-humored advice over the past 8 years as chair of the MSKCC Board of Scientific Counsellors. He knew how to criticize without insult, and how to praise without flattery. And he was wonderfully generous with his time. The world has lost one of its most outstanding physician-scientists, and his family and friends have lost a humane, politically engaged, and sensitive human being.

 

Harold Varmus
Memorial Sloan-Kettering

In his 15 years as director of the Kimmel Cancer Center, Dr. Martin Abeloff headed an outstanding institution, even as he continued to lead seminal research in breast cancer therapy and prevention. His contributions to the state of the science, in the use of mammography, and in techniques to screen for breast cancer risk factors, transformed prevention efforts. His death is one more reason we rededicate ourselves daily to the goals that Marty shared: trying to solve the mysteries of cancer so that future generations won't have to suffer unnecessarily.

 

Elias A. Zerhouni, MD, NIH
John E. Niederhuber, MD, NCI

Leadership of a department in an institution as complex as Johns Hopkins is a never-ending challenge and potentially ulcer-producing. Marty met the challenge and, as far as I know, managed to escape the ulcers. . . . Leadership that promotes and encourages growth of all who work in the department has been essential to the success of the past 30 years and will be the key to success in the coming decades.

 

David S. Ettinger, MD
Kimmel Cancer Center

Marty was one of the most decent and thoughtful leaders in our field. His death is a great loss, a real tragedy.

 

Steve Rosen, MD
Lurie Cancer Center

I am personally indebted to Marty Abeloff as he hired me and advanced my career, working as my mentor for my very first grant and my first clinical trial all the way through to helping me to become the occupant of the Breast Cancer Research Professor, an endowed chair for which he garnered the funds! So many of us at the Kimmel Cancer Center have enjoyed similar successes as Marty has served us individually and collectively through his leadership at the local, national, and international levels. Marty Abeloff reminds us that Leo Durocher was wrong—in fact, nice guys can finish first!

 

Nancy Davidson, MD
Kimmel Cancer Center

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 48-Year-Old Woman With Irregular Vaginal Bleeding
Brian Morse, MD1 , June 10, 2013

A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • Radiation-Induced Enteritis: Incidence, Mechanisms, and Management
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy